LALPATHLAB - IntraDay Trade Analysis with Live Signals

Last Updated Time : 05 Nov 25, 7:43 am

IntraDay Trade Rating: 3.6

📊 Stable fundamentals and trend support a tactical intraday setup, though weak momentum and volume suggest cautious positioning.

📈 Positive

• 📈 Trading above DMA 200 (₹3,017) — long-term trend remains intact.
• 📈 ROCE (30.6%) and ROE (24.7%) — excellent capital efficiency.
• 📈 DII holding increased by 0.60% — rising domestic institutional confidence.
• 📈 Debt-to-equity ratio of 0.06 — low financial risk.

⚠️ Limitation

• 📉 MACD at -13.9 — bearish divergence, momentum remains weak.
• 📉 Volume below average (1.51L vs 2.47L) — muted intraday participation.
• 📉 RSI at 49.9 — neutral zone, lacks strong bullish confirmation.
• 📉 P/E of 50.1 vs industry P/E of 43.2 — trades at a premium.

📰 Company Negative News

• 📉 MACD and volume suggest limited momentum for aggressive intraday moves.

🌟 Company Positive News

• 📈 PAT rose from ₹129 Cr. to ₹146 Cr. — 13.1% quarterly growth.
• 📈 EPS of ₹63.2 — strong earnings base.
• 📈 FII holding increased by 0.17% — mild foreign investor confidence.

🧪 Industry

• 🧬 Operates in diagnostics and pathology — defensive sector with consistent demand and healthcare tailwinds.
• 📊 Industry P/E of 43.2 — LALPATHLAB trades at a slight premium, reflecting brand strength.

📌 Conclusion

• 📈 Moderate intraday potential with strong fundamentals and trend support, but weak momentum and volume suggest tight risk control.
• 💡 Optimal buy range: ₹3,155–₹3,160. Target exit: ₹3,175–₹3,190.
• 🛑 Stop-loss: ₹3,140 to manage downside risk.
• 📤 If already holding, consider exiting near ₹3,175 if RSI crosses 52 or MACD flattens intraday.

I can also help you compare LALPATHLAB’s setup with other healthcare stocks showing stronger MACD and RSI signals for intraday trades.